milestone payments

Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program

5 months ago talkbio0Tagged Collaboration, factor IX, global license agreement, Huntington 's disease, milestone payments, Novartis, Phase 2 drug

Novartis, PTC Therapeutics, Huntington’s disease, Phase 2 drug, global license agreement, collaboration, upfront payment, milestone payments.

Sangamo Secures $50M Upfront in Neurodegenerative Pact with Roche’s Genentech

9 months ago talkbio0Tagged biobucks, genentech, milestone payments, Neurodegenerative, Roche (company), Sangamo

Sangamo, Roche, Genentech, neurodegenerative, biotech, licensing deal, milestone payments, biobucks

AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront

9 months ago talkbio0Tagged AstraZeneca, Cancer Therapeutic Procedure, Epidermal Growth Factor Receptor, licensing agreement, milestone payments, molecular glues, Neoplasms, Pinetree, Protein Degradation, Metabolic, protein degrader, royalties

AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet

1 year ago talkbio0Tagged Alnylam, blood pressure medication, Hypertension therapy, KARDIA-2, milestone payments, Partnership, RNA Interference, Roche (company), Systolic blood pressure reduction, Zilebesiran

Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study

Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy

1 year ago talkbio0Tagged 2025, Acoramidis, Approved, ATTR-CM, Bayer, Blockbuster Potential, BridgeBio Pharma, Cardiovascular Infrastructure, Clarity, Clinical action, EMA Approval, European Rights, Exclusive License, Hope (emotion), investor, low-thirties, milestone payments, November 2024, PDUFA, Phase 3 Data, royalties, Split Strategy, Vyndaqel Rival

Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.